Therefore, the association between DLAT and the drug response of tumor cells was explored to evaluate the therapeutic biomarker value of DLAT We exhibited that DLAT was positively associated with IC50 values of seven compounds, including PI3Kβ inhibitor (AZD6482), PKC inhibitor (midostaurin), HSP90 inhibitor (tanespimycin), and MEK inhibitors (PD0325901, refametinib, trametinib, selumetinib), which suggested that patients with increased DLAT were more resistant to these drugs. The gene discussed is MAP2K7; the disease is neoplasm.